IN2015MN00002A - - Google Patents
Info
- Publication number
- IN2015MN00002A IN2015MN00002A IN2MUN2015A IN2015MN00002A IN 2015MN00002 A IN2015MN00002 A IN 2015MN00002A IN 2MUN2015 A IN2MUN2015 A IN 2MUN2015A IN 2015MN00002 A IN2015MN00002 A IN 2015MN00002A
- Authority
- IN
- India
- Prior art keywords
- stereoisomer
- amenable
- disorders
- inhibiting
- prevention
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 abstract 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 abstract 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2MUN2015 IN2015MN00002A (fr) | 2012-07-09 | 2013-07-09 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN762KO2012 | 2012-07-09 | ||
| PCT/IB2013/055618 WO2014009872A1 (fr) | 2012-07-09 | 2013-07-09 | Dérivés tétrahydroquinazolinone utilisés comme inhibiteurs de parp |
| IN2MUN2015 IN2015MN00002A (fr) | 2012-07-09 | 2013-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015MN00002A true IN2015MN00002A (fr) | 2015-10-16 |
Family
ID=48906465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2MUN2015 IN2015MN00002A (fr) | 2012-07-09 | 2013-07-09 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9359367B2 (fr) |
| EP (1) | EP2870140B8 (fr) |
| AU (1) | AU2013288265B2 (fr) |
| CA (1) | CA2877826C (fr) |
| ES (1) | ES2595240T3 (fr) |
| IN (1) | IN2015MN00002A (fr) |
| WO (1) | WO2014009872A1 (fr) |
| ZA (1) | ZA201409497B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ725165A (en) * | 2014-04-10 | 2018-04-27 | Hubei Bio Pharmaceutical Industrial Tech Institute Inc | Analogues of 4h-pyrazolo[1,5-α]benzimidazole compound as parp inhibitors |
| WO2016012956A1 (fr) * | 2014-07-24 | 2016-01-28 | Lupin Limited | Dérivés d'isoquinolinone utilisés en tant qu'inhibiteurs de parp |
| WO2017013593A1 (fr) | 2015-07-22 | 2017-01-26 | Lupin Limited | Dérivés d'isoquinolinone utilisés en tant qu'inhibiteurs de parp |
| HK1255269A1 (zh) * | 2015-08-17 | 2019-08-09 | Lupin Limited | 作为parp抑制剂的杂芳基衍生物 |
| CN108822115B (zh) * | 2017-04-21 | 2022-08-12 | 上海迪诺医药科技有限公司 | 一种抑制parp活性的化合物的制备方法及其中间体 |
| EP3728207B1 (fr) * | 2017-12-21 | 2023-02-01 | Ribon Therapeutics Inc. | Quinazolinones en tant qu'inhibiteurs de parp14 |
| CN111269216A (zh) * | 2018-12-05 | 2020-06-12 | 中国医学科学院药物研究所 | 含有哌嗪酮的喹唑啉二酮盐类化合物、其制备方法、药物组合物和用途 |
| US20220291240A1 (en) * | 2019-08-27 | 2022-09-15 | The Johns Hopkins University | Biomarkers for neurodegenerative disorders |
| TWI749881B (zh) * | 2019-11-21 | 2021-12-11 | 大陸商深圳信立泰藥業股份有限公司 | 二氧代哌類衍生物、其製備方法及其在醫藥上的應用 |
| CN112608303B (zh) * | 2020-12-25 | 2021-10-26 | 华南理工大学 | 一种哌嗪类中间体及其制备方法与应用 |
| CN114044769B (zh) * | 2021-11-25 | 2023-12-12 | 中山大学 | 一种β-吲哚喹唑啉酮衍生物及其制备方法和应用 |
| US20250152585A1 (en) * | 2022-02-16 | 2025-05-15 | Duke Street Bio Limited | Pharmaceutical compound |
| GB2634233A (en) * | 2023-10-02 | 2025-04-09 | Duke Street Bio Ltd | PARP1 inhibitor compounds |
| WO2025091346A1 (fr) * | 2023-11-01 | 2025-05-08 | Suzhou Eoc Medical Research Co., Ltd. | Inhibiteurs de parp et leurs utilisations |
| WO2025101854A1 (fr) * | 2023-11-09 | 2025-05-15 | University Of Kentucky Research Foundation | Composés opioïdes |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2027645A1 (de) | 1970-06-05 | 1971-12-09 | Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz | Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel |
| BE503170A (fr) | 1975-09-02 | |||
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| IL90858A (en) | 1988-07-07 | 1994-08-26 | Rhone Poulenc Sante | Derivatives of (AZA) naphthalensultam, their preparation and compositions containing them |
| DE4312832C1 (de) | 1993-04-20 | 1994-10-20 | Boehringer Ingelheim Kg | Verfahren zur Herstellung enantiomerenreiner Ketale der (S)- und (R)-3-Oxocyclopentancarbonsäure |
| DE4316576A1 (de) | 1993-05-18 | 1994-11-24 | Boehringer Ingelheim Kg | Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin |
| US5589489A (en) | 1993-12-15 | 1996-12-31 | Zeneca Limited | Cyclic amide derivatives for treating asthma |
| GB9904275D0 (en) | 1999-02-24 | 1999-04-21 | Cancer Res Campaign Tech | Anti-cancer compounds |
| US20020082268A1 (en) | 2000-03-20 | 2002-06-27 | Yun Gao | Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof |
| ES2211738T3 (es) | 2000-08-03 | 2004-07-16 | Pfizer Products Inc. | Derivados de diazabiciclooctano y sus usos terapeuticos. |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| EP1396488A1 (fr) * | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Compose heterocyclique condense et son utilisation medicale |
| HRP20040069A2 (en) | 2001-07-11 | 2005-02-28 | Elan Pharmaceuticals Pharmacia & Upjohn Company | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds |
| AUPR975601A0 (en) | 2001-12-24 | 2002-01-31 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
| AUPS019702A0 (en) | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| AU2003262747A1 (en) | 2002-08-21 | 2004-03-11 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| CN1266155C (zh) | 2003-08-01 | 2006-07-26 | 浙江震元制药有限公司 | 6－氯－4－羟基－2－甲基－2H－噻吩并（2，3－e）－1，2－噻嗪－1，1－二氧化物－3－羧酸酯的合成方法 |
| US7772240B2 (en) | 2003-08-18 | 2010-08-10 | H. Lundbeck A/S | Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
| US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
| ES2371469T3 (es) | 2003-12-01 | 2012-01-03 | Kudos Pharmaceuticals Limited | Inhibidores de reparación de daños en adn para el tratamiento del cáncer. |
| US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
| WO2005082887A1 (fr) | 2004-02-26 | 2005-09-09 | Aska Pharmaceutical Co., Ltd. | Dérivé de pyrimidine |
| US7381822B2 (en) | 2004-03-31 | 2008-06-03 | The General Hospital Corporation | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process |
| US20050245534A1 (en) | 2004-04-29 | 2005-11-03 | Link James T | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| US9212149B2 (en) | 2004-04-30 | 2015-12-15 | Takeda Pharmaceutical Company Limited | Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors |
| CN1976906B (zh) | 2004-06-30 | 2010-09-01 | 詹森药业有限公司 | 用作parp抑制剂的取代2-烷基喹唑啉酮衍生物 |
| US20060079510A1 (en) | 2004-09-30 | 2006-04-13 | Kristoffer Hellstrand | Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis |
| EP1820799A1 (fr) | 2004-11-10 | 2007-08-22 | Wakamoto Pharmaceutical Co., Ltd. | Dérivé de 2,3,4,5-tétrahydro-1h-1,5-benzodiazépine et préparation thérapeutique |
| MX2007007272A (es) | 2004-12-17 | 2007-07-11 | Astrazeneca Ab | 4-(4-imidazol-4-il)pirimidin-2-ilamino)benzamidas como inhibidores de cdk. |
| EP1863787B1 (fr) | 2005-03-23 | 2011-05-25 | Actelion Pharmaceuticals Ltd. | Derives hydrogenes de benzo (c) thiophene utilises comme immunomodulateurs |
| WO2006137510A1 (fr) | 2005-06-24 | 2006-12-28 | Ono Pharmaceutical Co., Ltd. | Agent pour réduire le saignement lors de troubles cérébrovasculaires |
| US7300947B2 (en) | 2005-07-13 | 2007-11-27 | Banyu Pharmaceutical Co., Ltd. | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
| WO2007011623A1 (fr) | 2005-07-15 | 2007-01-25 | Schering Corporation | Derives de quinazoline utiles pour traiter le cancer |
| WO2007062413A2 (fr) | 2005-11-25 | 2007-05-31 | University Of Medicine And Dentistry Of New Jersey | Utilisation d'inhibiteurs du parp-1 |
| US20070197509A1 (en) | 2005-12-21 | 2007-08-23 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
| WO2007076055A2 (fr) | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions et methodes comprenant l'utilisation d'antagonistes du recepteur active par des proteases |
| EP2010505B1 (fr) | 2006-03-28 | 2012-12-05 | Atir Holding S.A. | Composés hétérocycliques et leurs utilisations dans le traitement de troubles sexuels |
| EP2041139B1 (fr) | 2006-04-26 | 2011-11-09 | F. Hoffmann-La Roche AG | Composés pharmaceutiques |
| WO2008080824A1 (fr) | 2006-12-29 | 2008-07-10 | F. Hoffmann-La Roche Ag | Cétales aromatiques sulfonés |
| US20100234363A1 (en) | 2007-09-19 | 2010-09-16 | Institute Of Medicinal Molecular Design, Inc. | Heterocyclic derivative having inhibitory activity on type-i 11 data-hydroxysteroid dehydrogenase |
| WO2009041565A1 (fr) | 2007-09-26 | 2009-04-02 | Santen Pharmaceutical Co., Ltd. | Dérivé de quinazolinone, et agent prophylactique ou thérapeutique des troubles cornéens/conjonctivaux comprenant ledit dérivé comme principe actif |
| WO2009041566A1 (fr) | 2007-09-26 | 2009-04-02 | Santen Pharmaceutical Co., Ltd. | Prophylaxie ou thérapie de maladies du segment postérieur de l'oeil faisant intervenir un dérivé de quinazolinone ou un dérivé de quinoxaline comme principe actif |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| FR2926221A1 (fr) | 2008-01-14 | 2009-07-17 | Tassin Thomas | Compositions permettant la reproduction artificielle des conditions pharmacologiques de la dependance aux drogues addictives telles que opiaces, psychostimulants, tabac et alcool, par la combinaison de nicotine et d'un ligand. |
| WO2009114459A2 (fr) | 2008-03-10 | 2009-09-17 | The Trustees Of The University Of Pennsylvania | Régime thérapeutique antinéoplasique combiné comprenant la co-disruption de la voie parp et du complexe mre11/rad50/nbs1, et compositions utiles à cette fin |
| CN102232076B (zh) | 2008-12-05 | 2014-12-31 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪基脲激酶抑制剂 |
| WO2010082813A1 (fr) | 2009-01-13 | 2010-07-22 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Procédé de traitement du cancer |
| AU2011229862B2 (en) | 2010-03-25 | 2014-07-24 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN103228141B (zh) | 2010-09-03 | 2016-04-20 | 拜耳知识产权有限责任公司 | 取代的稠合的嘧啶酮和二氢嘧啶酮 |
-
2013
- 2013-07-09 IN IN2MUN2015 patent/IN2015MN00002A/en unknown
- 2013-07-09 EP EP13742752.2A patent/EP2870140B8/fr not_active Not-in-force
- 2013-07-09 CA CA2877826A patent/CA2877826C/fr not_active Expired - Fee Related
- 2013-07-09 WO PCT/IB2013/055618 patent/WO2014009872A1/fr not_active Ceased
- 2013-07-09 US US14/411,968 patent/US9359367B2/en not_active Expired - Fee Related
- 2013-07-09 ES ES13742752.2T patent/ES2595240T3/es active Active
- 2013-07-09 AU AU2013288265A patent/AU2013288265B2/en not_active Ceased
-
2014
- 2014-12-23 ZA ZA2014/09497A patent/ZA201409497B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013288265B2 (en) | 2017-04-06 |
| ZA201409497B (en) | 2015-12-23 |
| EP2870140B8 (fr) | 2016-09-28 |
| CA2877826C (fr) | 2016-08-16 |
| AU2013288265A1 (en) | 2015-01-29 |
| ES2595240T3 (es) | 2016-12-28 |
| EP2870140A1 (fr) | 2015-05-13 |
| WO2014009872A1 (fr) | 2014-01-16 |
| US9359367B2 (en) | 2016-06-07 |
| EP2870140B1 (fr) | 2016-07-27 |
| CA2877826A1 (fr) | 2014-01-16 |
| US20150152118A1 (en) | 2015-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015MN00002A (fr) | ||
| PH12018500360A1 (en) | Heteroaryl derivatives as parp inhibitors | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| PH12015501517A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| MX352672B (es) | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| PH12018500040A1 (en) | Indazole and azaindazole compounds as irak-4 inhibitors | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| MX368703B (es) | Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer. | |
| MX2011009796A (es) | Inhibidores de la cinasa pi3. | |
| MY199894A (en) | Prmt5 inhibitors and uses thereof | |
| MY199131A (en) | Human plasma kallikrein inhibitors | |
| MD4659B1 (ro) | Polimorf al inhibitorilor SYK | |
| MX2014014106A (es) | Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral. | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| PH12017500007A1 (en) | Quinolizinone derivatives as p13k inhibitors | |
| MX2013011591A (es) | Métodos y composiciones para tratar enfermedades neurodegenerativas. | |
| WO2014155300A3 (fr) | Dérivés pyrimidine aminée substitués en tant qu'inhibiteurs de tak-1 | |
| MY184858A (en) | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors | |
| NZ706591A (en) | Oxazolidin-2-one-pyrimidine derivatives | |
| MX2014003801A (es) | Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
| MX2015010619A (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer. | |
| MX2015008288A (es) | Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
| MY184561A (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
| MX2016004967A (es) | Tratamiento para cancer pancreatico. |